Akorn (www.akorn.com) reports that it has added two injectable drug products to its API Supply and Margin Sharing Agreement with Natco Pharma (www.natcopharma.co.in). One ANDA drug product is indicated for the prevention of nausea and vomiting associated with cancer chemotherapy, while the other ANDA drug product is indicated in the reduction of renal toxicity and xerostomia in cancer patients undergoing chemotherapy and radiation. Natco will be responsible for the supply of the API for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing, and distribution in the hospital, clinic, and home healthcare markets in the U.S. and Canada.
